A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Study Purpose:

The primary objective of this study is to demonstrate a pharmacodynamic effect of CK 2017357 on measures of skeletal muscle function or fatigability in patients with ALS.


Amyotrophic Lateral Sclerosis (ALS),  Familial ALS,  Sporadic ALS

Study Type:

Interventional Trial

Study Category:

Drug Trial

Study Status:

Not enrolling


Phase II

Study Chair(s)/Principal Investigator(s):

Jeremy M Shefner, MD, PhD (State University of New York - Upstate Medical University)

Clinicaltrials.gov ID (11 digit #):


Neals Affiliated?


Coordinating Center Contact Information

State University of New York - Upstate Medical University
.(JavaScript must be enabled to view this email address)
.(JavaScript must be enabled to view this email address) Syracuse, New York 13210 United States

Full Study Summary:

This study is a Phase II, double-blind, randomized, placebo-controlled, three-way crossover study of CK-2017357 in patients with ALS. 36 to 72 patients will be randomized to one of six different treatment sequences. Each treatment sequence consists of three dosing periods; in each dosing period, patients receive a single oral dose of placebo, 250 mg of CK-2017357, or 500 mg of CK-2017357. All six treatment sequences will enroll approximately the same number of patients. A washout period of at least 6 days (to a maximum of 10 days) will be employed between the doses for each patient. This study is designed to assess the effect of CK-2017357 on maximal voluntary muscle strength, on the development of fatigue at maximal and sub-maximal voluntary muscle contraction, and on selected pulmonary function parameters. The plasma concentration of CK-2017357 will be measured at selected time points after each of two single doses of CK-2017357 in men and women. The plasma concentration versus time data obtained in this study may be used to develop a population PK model and estimate inter-subject variability of PK parameters in this target patient population, in particular between male and female study patients.

Study Sponsor:


Participant Duration:

Estimated Enrollment:


Estimated Study Start Date:


Estimated Study Completion Date:


Posting Last Modified Date:


Date Study Added to alsconsortium.org:

  • Eligibility Criteria


    Female, Male

    Minimum Age:


    Maximum Age:


    Min Vital Capacity (% predicted normal):


    Time since Symptom Onset:


    Time since Diagnosis:


    Can participants use Riluzole?

    Inclusion Criteria:

    •Able to comprehend and willing to sign an Informed Consent Form (ICF)
    •A diagnosis of familial or sporadic ALS (defined as meeting the possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS according to the World Federation of Neurology El Escorial criteria) (Brooks, et al., 2000)
    •Males or Females 18 years of age or older
    •Body mass index (BMI) of 18.0 to 30.0 kg/m2, inclusive
    •Maximum voluntary grip strength between 10 & 40 pounds (females) and 10 & 60 pounds (males)
    •Able to maintain grip contraction for 15 seconds
    •Upright Slow Vital Capacity (SVC) ≥40% of predicted for age, height, and sex
    •Able to perform pulmonary function tests
    •Pre-study clinical laboratory findings (including troponin I (TnI) and CPK) within normal range, or if outside of the normal range, deemed not clinically significant by the Investigator
    •For female patients only: The patient is post-menopausal (≥ 1 year) or sterilized, or if she is of childbearing potential, she is not breastfeeding, her pregnancy test is negative, she has no intention to become pregnant during the course of the study, and she is using contraceptive drugs or devices. For male patients only: Male patients agree for the duration of the study and 10 weeks after the end of the study to use a condom during sexual intercourse with female partners who are of reproductive potential and to have female partners use an additional effective means of contraception (e.g., diaphragm plus spermicide, or oral contraceptives) or the male patient must agree to abstain from sexual intercourse for 10 weeks after the end of the study.

    Exclusion Criteria:

    •Significant hepatic/renal insufficiency as defined by Upper Limit of Normal (ULN) laboratory findings
    •Life expectancy <3 months
    •Participation in any trial in which receipt of investigational study drug occurred within 30 days prior to dosing
    •Any prior treatment with CK-2017357
    •In the opinion of the Investigator, the patient is not suitable to participate in the study

  • Site Contact Information

    Phoenix Neurological Associates, Ltd.
    Phoenix, Arizona 85018
    United States

    University Neurology Associates
    Fresno, California 93701
    United States

    California Pacific Medical Center
    San Francisco, California 94115
    United States

    Mayo Clinic Florida
    Jacksonville, Florida 32224
    United States

    University of Kentucky
    Lexington, Kentucky 40536
    United States

    Johns Hopkins Hospital
    Baltimore, Maryland 21287
    United States

    Massachusetts General Hospital
    Boston, Massachusetts 02114
    United States

    Washington University
    St Louis, Missouri 63110
    United States

    SUNY Upstate Medical Center
    Syracuse, New York 13210
    United States

    Duke University
    Durham, North Carolina 27705
    United States

    Providence ALS Center
    Portland, Oregon 97213
    United States

    Drexel University College of Medicine, Dept of Neurology
    Philadelphia, Pennsylvania 19102
    United States

    Penn State
    University Park, Pennsylvania 17033
    United States

    The University of Texas Health Science Center at San Antonio
    San Antonio, Texas 78229
    United States

    University of Vermont
    Burlington, Vermont 05401
    United States

  • Study Results